PSV ventilation strategy
OtherAn algorithm for adjusting the level of pressure support according to usual clinical parameters; patients not tolerating PSV will be switched to Assist/Control mode according to predefined criteria
NCT Number: NCT02447692
For adult patients with acute respiratory failure requiring invasive mechanical ventilation, does a ventilation strategy using proportional assist ventilation with load-adjustable gain factors (PAV+) result in a shorter duration of time spent on mechanical ventilation than a ventilation strategy using pressure support ventilation (PSV)?
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
El Centro de Educación Médica e Investigaciones Clínicas "Norberto Quirno", Buenos Aires, Argentina
Patients with acute respiratory failure require mechanical ventilation to help them breathe until they recover from their acute illness. Although mechanical ventilation is necessary to sustain life in such situations, it can induce weakness of the respiratory muscles which may lead to prolonged dependence on the ventilator. Prolonged dependence on mechanical ventilation is associated with increased mortality, morbidity and costs to the healthcare system. Thus, a main goal of assisted mechanical ventilation is to reduce the patient's respiratory distress while maintaining some respiratory muscle activity. To attain this goal, the amount of ventilator assistance should theoretically be adjusted to target normal or reasonable levels of respiratory effort.
Modes of Mechanical Ventilation:
Proportional assist ventilation with load-adjustable gain factors (PAV+) is a mode of mechanical ventilation which delivers assistance to breathe in proportion to the patient's effort. The proportional assistance, called the gain, can be adjusted by the clinician to maintain the patient's respiratory effort or workload within a reasonable range. This is the only mode of ventilation which allows for measurement and targeting of a specific range of respiratory muscle activity by the patient.
Pressure support ventilation (PSV) is a mode of ventilation which is considered the current standard of care for assisting breathing of patients during the recovery phase of acute respiratory failure. Several studies have shown short term advantages of PAV over PSV, including improved patient-ventilator synchronization, improved adaptability to changes in patient effort, and improved sleep quality.
Goal of this Randomized Controlled Trial:
To demonstrate that for patients with acute respiratory failure, ventilation with PAV+, being more physiological, will result in a shorter duration of time spent on mechanical ventilation than ventilation with PSV.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
A staged enrolment process will be used to identify patients eligible to be enrolled and randomized in the study. At each stage of the enrolment process, a patient must meet inclusion criteria and not meet exclusion criteria in order to pass. To progress to the next stage, patients must continue to pass criteria from the prior stages. After enrolment, there are also specific tests to perform (with pass/fail criteria) to determine eligibility to be randomized.
A. SCREENING INCLUSION CRITERIA:
A. SCREENING EXCLUSION CRITERIA:
B. ENROLMENT INCLUSION CRITERIA:
B. ENROLMENT EXCLUSION CRITERIA:
B. ENROLMENT DEFERRAL CRITERIA:
C. PRESSURE SUPPORT TRIAL INCLUSION CRITEIRA:
C. PRESSURE SUPPORT TRIAL DEFERRAL CRITERIA:
C. PRESSURE SUPPORT TRIAL EXCLUSION CRITERIA:
D. WEANING CRITERIA:
In the final stage (E), patients will be considered eligible for randomization if the following criteria are met.
E. RANDOMIZATION INCLUSION CRITERIA:
E. RANDOMIZATION EXCLUSION CRITERIA:
An algorithm for adjusting the level of pressure support according to usual clinical parameters; patients not tolerating PSV will be switched to Assist/Control mode according to predefined criteria
An algorithm for adjusting the level of support (gain) to maintain a predefined range of respiratory muscle pressure; patients not tolerating PAV+ (Puritan Bennett™ 840 or 980 ventilator) will be switched to Assist/Control mode according to predefined criteria
Time frame: up to 90 days
"Successful liberation" is defined as removal of the endotracheal tube AND remaining alive with no need for reintubation/reinstitution of invasive mechanical ventilation for 7 days post extubation, or until successful ICU discharge, or until live hospital discharge, whichever comes first.
Time frame: 14, 21 and 28 days post randomization
"Ventilator-free days" (VFDs) are defined as the number of days alive and free of INVASIVE ventilation post SUCCESSFUL EXTUBATION or post successful termination of invasive mechanical ventilation (MV) from time of randomization to day 21 post randomization. "Successful extubation" is defined as removal of the endotracheal tube AND remaining alive with no need for reintubation/reinstitution of invasive mechanical ventilation for 7 days post extubation, or until successful ICU discharge, or until live hospital discharge, whichever comes first.
Time frame: up to 90 days
Patients will remain in the study and will continue on the assigned ventilation strategy until: successful extubation, successful ICU discharge, live hospital discharge, death, or 90 days post randomization, whichever comes first.
Time frame: up to 90 days
Patients will remain in the study and will continue on the assigned ventilation strategy until: successful extubation, successful ICU discharge, live hospital discharge, death, or 90 days post randomization, whichever comes first.
Time frame: up to 90 days
Measured as time to death, ICU mortality; hospital mortality; 21, 28, and 90 day mortality
Time frame: up to 90 days
Measured as time from randomization to: first SBT; first successful SBT; first extubation
Time frame: 90 days
Measured as the number of patients failing first SBT or first extubation attempt and requiring up to 7 days to extubate (difficult weaning group/group 2); failing first SBT or first extubation attempt and requiring more than 7 days to extubate (prolonged weaning group/group 3)
Time frame: 90 days
Measured as the number of patients: requiring non-invasive ventilation post-extubation; ventilated more than 7 days post randomization, ventilated more than 21 days from time of intubation (prolonged MV group); receiving tracheostomy post-randomization, requiring re-intubation (up to 7d after planned extubation)
Time frame: 90 days
Measured as number of patients ever requiring A/C mode post randomization; number of patient-days requiring A/C mode post randomization
Time frame: 90 days
Incidence of reported serious adverse events
Time frame: 28 days
Co-interventions will be monitored and described including use of sedating medications
Time frame: At randomization
Identifies a subgroup of patients at time of randomization who are at risk for prolonged weaning
Time frame: At randomization
Identifies a subgroup of patients at time of randomization classified as difficult weaning vs. failed CPAP 0 trial vs. failed weaning criteria prior to randomization
Time frame: At randomization
Identifies a subgroup of patients at time of randomization classified as having "difficult weaning".
Time frame: At ICU admission
Differentiates between severely frail and less frail
Time frame: At ICU admission
Differentiates between COVID-19 positive and COVID-19 negative
Time frame: At randomization
Identifies a subgroup of patients at risk of prolonged weaning
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Other
Acronym: PROMIZING
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01713309
Acute Respiratory Failure, Critical Illness
Helsinki, Finland
View Trial DetailsNCT03793257
Acute Heart Failure, Acute Respiratory Failure
Canberra, Australian Capital Territory, Australia
View Trial DetailsNCT04957238
Aberrant Motor Behavior in Dementia, Agitation,Psychomotor
Aurillac, France
View Trial DetailsNCT07681544
Critical Illness, Critically Ill
Buenos Aires, Argentina
View Trial Details